KeyBanc reiterates Sector Weight rating on Hims and Hers stock

KeyBanc Capital Markets maintained a "Sector Weight" rating on Hims and Hers (HIMS), characterizing it as a "2H26 story" due to near-term subscriber growth challenges and significant investments in diagnostics, despite impressive 88.69% revenue growth and expected net income growth. While these diagnostic investments are seen as potential long-term catalysts, KeyBanc remains cautious given the stock's high volatility (beta 2.25) and elevated P/E ratio (57.01). This stance follows mixed Q3 earnings where revenue exceeded expectations but EPS missed, resulting in varied analyst sentiment ranging from 'Buy' to 'Underperform' across the Street.

Analysis

KeyBanc Capital Markets maintained a "Sector Weight" rating on Hims and Hers (HIMS), characterizing it as a "2H26 story" due to near-term subscriber growth challenges and significant investments in diagnostic capabilities. This neutral stance persists despite an impressive 88.69% revenue growth in the last twelve months and expected net income growth, with the firm advising prudence until new product scaling signs emerge.

HIMS reported mixed Q3 earnings, exceeding revenue expectations with $600 million against a $580.37 million forecast, but missing EPS at $0.06 versus an anticipated $0.10. The company demonstrates strong financial health with a current ratio of 4.98 and analysts forecast EPS of $1.33 for fiscal year 2025, yet its P/E ratio of 57.01 is considered high, and the stock exhibits significant volatility with a beta of 2.25.

KeyBanc views the diagnostic investments as a potential catalyst for attracting new subscribers and enhancing customer lifetime value, potentially driving positive estimate revisions for 2026 and 2027. Analyst sentiment remains varied post-Q3, with BTIG and Canaccord Genuity reiterating "Buy" ratings, while Needham holds a "Hold" and BofA Securities maintains an "Underperform" due to investment impacts and challenges in specific business segments.

Key Decisions for Investors

• Investors should consider HIMS a long-term growth opportunity, contingent on the successful scaling of diagnostic investments and resolution of near-term subscriber growth challenges.
• Monitor key performance indicators such as subscriber growth rates, the efficacy of new diagnostic products, and the impact of investments on future profitability and EPS revisions for 2026/2027.
• Given the stock's high volatility (beta 2.25) and elevated P/E ratio (57.01), a cautious approach to position sizing and entry points is advisable, particularly while awaiting clearer signs of new product traction.